Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals by Aline C A Mota-Miranda et al.
Mota-Miranda et al. Virology Journal 2013, 10:75
http://www.virologyj.com/content/10/1/75RESEARCH Open AccessMolecular characterization of HTLV-1 gp46
glycoprotein from health carriers and HAM/TSP
infected individuals
Aline C A Mota-Miranda1,2,3, Fernanda K Barreto1, Maria F C Amarante5, Everton Batista4,
Joana P Monteiro-Cunha2,3, Lourdes Farre4, Bernardo Galvão-Castro1,2 and Luiz C J Alcantara1*Abstract
Background: Human T-cell Leukemia Virus type 1 (HTLV-1) is the etiological agent of tropical spastic paraparesis/
HTLV-associated myelopathy (HAM/TSP) that can be identified in around 0.25%–3.8% of the infected population.
Disease progression can be monitored by the proviral load and may depend on genetic factors, however, it is not
well understood why some HTLV-1 infected people develop the disease while others do not. The present study
attempts to assess the molecular diversity of gp46 glycoprotein in HAM/TSP patients and Health Carrier (HC)
individuals.
Methods: Blood samples were collected from 10 individuals, and DNA was extracted from PBMCs to measure the
HTLV-1 proviral load. The gp46 coding sequences were amplified PCR, cloned and sequenced. The molecular
characterization was performed using bioinformatics tools.
Results: The median HTLV-1 proviral load of HC (n = 5) and HAM/TSP (n = 5) patients was similar (average 316,227
copies/106 PBMCs). The gp46 molecular characterization of 146 clones (70 HC and 76 HAM/TSP) revealed an overall
diversity, within HC and HAM/TSP clones, of 0.4% and 0.6%, respectively. Five frequent mutations were detected
among groups (HAM/TSP and HC clone sequences). A single amino acid (aa) substitution (S35L) was exclusive for
the HC group, and three gp46 substitutions (F14S, N42H, G72S) were exclusive for the HAM/TSP group. The
remaining frequent mutation (V247I) was present in both groups (p = 0.0014). The in silico protein analysis revealed
that the mutated alleles F14S and N42H represent more hydrophilic and flexible protein domains that are likely to
be less antigenic. The Receptor Binding Domain is quite variable in the HAM/TSP group. Two other domains
(aa 53–75 and 175–209) that contain multiple linear T-cell epitopes showed genetic diversity in both HAM/TSP and
HC groups. Further analysis revealed 27 and 13 T-cell epitopes for class I HLA alleles and class II HLA alleles, when
analyzing the entire gp46.
Conclusions: The most common gp46 mutations were not associated clinical status because they were found in
only one individual, except for the V247I mutation, that was found at viral clones from HAM/TSP ad HC individuals.
Because of this, we cannot associate any of the gp46 found mutations with the clinical profile.
Keywords: HTLV-1, HAM/TSP, Gp46, Mutation* Correspondence: lalcan@bahia.fiocruz.br
1Centro de Pesquisa Gonçalo Moniz, Fundação Oswaldo Cruz, CPqGM/
FIOCRUZ. Rua Waldemar Falcão 121, Brotas, Salvador, Bahia 40295-001, Brazil
Full list of author information is available at the end of the article
© 2013 Mota-Miranda et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1 Median of HTLV-1 proviral load in health carriers
(n = 5) and HAM/TSP (n = 5) individuals. Results are presented as
number of HTLV-1 copies/106 PBMCs. The box-plots represent the
median, interquartile range (boxes) and the 5–95% data range
(whisker caps).
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HTLV-1 was initially isolated from a patient with cutaneous
T-cell lymphoma in early 1980s, being the first discovered
human retrovirus [1]. HTLV-1 is classically the etiological
agent of tropical spastic paraparesis/HTLV-associated myel-
opathy (HAM/TSP), which is characterized, besides the
spastic paraparesis, by urinary disturbances and, in almost
all patients, spasticity and/or hyper-reflexia of the lower ex-
tremities [2]. HTLV-1 has also been implicated as the cause
of Adult T-cell Leukemia/Lymphoma (ATLL) and of other
inflammatory disorders such as arthritis, uveitis, dermatitis,
lymphadenitis and Sjogren’s syndrome [2].
It is estimated that around 0.25%–3.8% of the HTLV-1
infected population develops HAM/TSP [3-6]. Despite the
scarcity of data on the real prevalence of HAM/TSP in the
Brazilian population, the individual risk of disease de-
velopment is of considerable importance for HTLV-1 en-
demic areas such as southern Japan, the Caribbean,
Central and South America (including Brazil), the Middle
East, Melanesia, and equatorial regions of Africa [4]. The
progression to HAM/TSP includes viral factors such as
proviral load and host genetic factors such as Human
Leukocyte Antigen (HLA). Most clinical studies associate
proviral load to increased risk of disease progression, and
in some of them, the HTLV-1 proviral load progressively
increases according to HAM/TSP ascertainment level
(possible, probable, and definite) of the De Castro-Costa
diagnostic criteria [7,8]. On the other side, molecular data
from southern Japan indicates that the alleles HLA-A*02
and Cw*08 (HLA class I) are associated with a significant
reduction in both HTLV-1 proviral load and the risk of
HAM/TSP, whereas HLA-B*5401 (HLA class I) and
HLA-DRB1*0101 (HLA class II) predispose to HAM/TSP
in the same population [9,10].
Although most studies of HTLV-1 genotype have
reported no association between HTLV-1 variants and risk
to HAM/TSP, it is known that HAM/TSP patients gene-
rally have higher anti-HTLV-1 antibody titer than Health
Carriers (HC) with a similar proviral load [11]. Addition-
ally, the antibody reactivity to Tax epitopes can be differ-
ent between HAM/TSP (71%–93%) and HC (27%–37%)
individuals [12]. Regarding the regulatory protein geno-
types, a p12 K88 allele was found mainly among HAM/
TSP individuals, suggesting that it could be implicated as
a pathogenesis marker [13].
The HTLV-1 envelope glycoproteins (Env) mediate the
binding of the virus to its receptor on the surface of target
cells and the subsequent fusion of virus and cell mem-
branes. It is also important to note that three different mo-
lecules are assumed to participate in HTLV-1 entry: a
glucose transporter type 1 (GLUT-1), the VEGF-165 recep-
tor Neuropilin 1 (NRP-1), and heparan sulfate proteogly-
cans (HSPG) [14-16]. Throughout the characterization of
neutralizing antibodies and analysis of Env mutants, it isnow known that gp46 contains a great number of func-
tional and immunodominant domains that are associated
to the prevalence of linear epitopes, interaction to neuro-
philin 1 or heparan sulfate molecules, and induction of
antibodies [13,17-20].
Because it is not well understood why some HTLV-1
infected people develop disease while others do not, the
purpose of the present study was to assess the molecular
diversity of gp46 glycoprotein in HAM/TSP and HC in-
dividuals to identify the potential molecular biomarkers
and/or the therapeutic targets for HAM/TSP. Despite
the lack of association with the clinical status, five fre-
quent mutations at gp46 were identified.
Results
Sample characterization
Blood samples were collected from 10 HTLV-1 infected
individuals recruited from a reference health unit: 5 HC
and 5 HAM/TSP patients. Because the progression to
HAM/TSP is multifactorial and is not only dependent on
viral factors, but also on the host’s genetic background, we
choose all individuals with similar proviral load and age.
The median HTLV-1 proviral load of HC and HAM/TSP
patients was the same (316,227 copies/106 PBMCs) (Fisher
Test, p = 0.0007-after Bonferroni Correction) (Figure 1),
while the median age was 53 (38–72) and 58 (41–73) years
for HC and HAM/TSP patients, respectively (p = 0.239).
Molecular characterization of gp46 glycoprotein
We obtained 146 gp46 clone sequences (908pb, 302aa):
70 from HC (average of 14 clones per individual) and 76
from HAM/TSP individuals (average of 15 clones per in-
dividual). The HC and HAM/TSP clone sequence overall
diversity was 0.4% and 0.6%, respectively. Regarding the
amino acid changes, we identified five mutations with
Figure 3 Genetic diversity of HTLV-1 gp46 functional domains
in Health Carrier (HC) and HAM/TSP clone sequences. aa means
amino acid.
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Among these common mutations, one (S35L) was exclu-
sive to the HC group, three (F14S, N42H, G72S) were
exclusive to the HAM/TSP group and, finally, one muta-
tion (V247I) was found in both groups but with a statis-
tically significant difference in the frequency within the
groups (Fisher Test, p = 0.0014).
Among the five mutations found, three (F14S, S35L
and N42H) were not present in any of the 42 Brazilian
sequences used to create the consensus. G72S was found
in one Brazilian sequence; however, we do not have in-
formation about the geographic region from which the
sequence was obtained. Finally, the V247I mutation was
found in sequences from all different geographic regions
represented in our dataset. Similarly, F14S, S35L, N42H
and V247I mutations were not present in any sequence
of the Cosmopolita dataset, while G72S mutation was
found in sequences from Gabon, Martinique, French
Guyana and Guadalupe.
We used the already known gp46 functional domains to
perform the search for mutations (See Additional file 1).
In general, the Receptor Binding Domain (RBD) presented
the greatest number of amino acid changes in both
groups. However, the general diversity (frequent and not
frequent mutations) profile is different between the HC
and HAM/TSP groups. The HC group presented the
three most divergent domains, and one of them is also a
divergent domain in the HAM/TSP group (Figure 3). It is
interesting to note that the second most divergent domain
(175-209 aa) in the HC group is characterized by theFigure 2 Frequency (%) of the most common amino acid
changes at gp46 clone sequences from HAM/TSP infected
individuals and Health Carriers (HC). N is the number of
clone sequences.prevalence of linear epitopes, and it was not so divergent
in the HAM/TSP group. It was also noticeable that the
domain 53-75 aa, associated to the most prevalent occur-
rence of linear epitopes, had the second higher index of
divergence among the HAM/TSP group (Figure 3). This
domain is less divergent in the HC group of clones. The
197 amino acid site, which was already associated to the
decrease in cellular fusion, was mutated (D197N) in two
clone sequences in our data set: one from the HC group
and the other from the HAM/TSP group (data not shown).
Moreover, one HAM/TSP sequence was mutated (Y80C)
at position 80 aa, which is part of the YSLY motif involved
in the protein trafficking to the plasma membrane.
We also performed the epitope prediction in the do-
mains with the higher genetic diversity in HAM/TSP
(53-75 aa) and HC clones (175-209 aa). Analyzing the
175-209 aa domain, 16 HLA-I and seven HLA-II specific
epitopes were found (Table 1). On the other hand, 11
HLA-I and five HLA-II specific epitopes were identified in
the 53-75 aa domain (Table 2). Since the G72S mutation
is located in the 53-75 aa domain, we tested both wild type
and mutated alleles. The mutated allele was associated
with change in HLA binding score in three of the 11 epi-
topes including this position (72 aa). For the HLA A26
and A01 (HLA-I) specific epitopes, starting at positions
65 aa and 68 aa, the HLA binding score increased and de-
creased, respectively (Table 2). For the HLA DRB1 0101
(HLA-II) specific epitope, starting at position 64 aa, the
HLA binding score decreased (Table 2).
To identify if the amino acid mutations found has
been positively selected, we have performed positive se-
lective pressure analysis. According to our results, the ω
value calculated for the clone sequences from HAM/
Table 1 Possible epitopes for classes I and II HLA alleles in HTLV-1 gp46 175-209 aa domain
A-Class I HLA alleles
AA position Epitope sequence HLA allele
175 F L N T E P S Q L A 0201, B 08
177 N T E P S Q L P P A 01, A 1101, B 4501
179 E P S Q L P P T A A 0702
182 Q L P P T A P P L A 0201, B 08, B 4402
183 L P P T A P P L L A 0701, B 08, B 5101
184 P P T A P P L L P B 0702
185 P T A P P L L P H A 1101
188 P P L L P H S N L B 0702, B 02, B 1402, B 2705, B 37, B 5101
191 L P H S N L D H I B 4901, B 5101
192 P H S N L D H I L B 1510, B 3801 B 3901
193 H S N L D H I L E A 1101
194 S N L D H I L E P B 4501
199 I L E P S I P W K A 03, A 1101, A 6801, B 2705
202 P S I P W K S K L A 26, B 2705
203 S I P W K S K L L A 0201, B 08, B 37
205 P W K S K L L T L A 26, B 3901
B-Class II HLA alleles
AA position Epitope sequence HLA allele
172 P I W F L N T E P S Q L P P T DRB 0701
180 P S Q L P P I A P P L L P H S DRB 0301, DRB 0701
187 A P P L L P H S N L D H I L E DRB 0301, DRB 1501
188 P P L L P H S N L D H I L E P DRB 0701
193 H S N L D H I L E P S I P W K DRB 0701
194 S N L D H I L E P S I P W K S DRB1 0101
201 E P S I P W K S K L L T L V Q DRB 1501
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for the clone sequences from HC individuals. Despite
this result no calculated ω value was >1.
The identification of post-translation modification sites
is summarized in Table 3 and shows that the same po-
tential protein domains were found among the HC and
HAM/TSP groups of sequences. However, despite being
the same sites, their frequencies were statistically diffe-
rent, being more frequent among the viral clones iso-
lated from HAM/TSP individuals (Table 3).
We submitted wild type and mutated sequences to
physico-chemical analysis using the NPSA tool. The fol-
lowing was observed: 1) the mutated allele presenting
the F14S mutation was more hydrophilic and flexible
than the wild type allele (Figure 4A); 2) the mutated al-
lele presenting the N42H mutation was less antigenic
than the wild type allele (Figure 4B); 3) the mutated al-
lele presenting the V247I mutation was less antigenic
than the wild type allele (Figure 4C). According to our
results, other less frequent mutations were associated to
changes in the physico-chemical profile and potential
protein domains: the T142I mutation was associated tothe loss of a N-glycosylation site and to a decrease in an-
tigenicity; the F159S mutation presented a more hydro-
philic and flexible profile, associated to the insertion of a
N-Myristilation site; and the H290D, C289R and F141S
mutations were characterized by an increase in hydro-
philicity and flexibility, the opposite of the D197N muta-
tion which was associated to a decrease in flexibility
(Data not shown).
After submission of wild type and mutated sequences
to SWISS-MODEL server, the results showed that the
S35L and G72S mutations were associated to the change
of coil for extended beta at the secondary structure pre-
diction (Figure 5).
Discussion
The low overall genetic diversity found in gp46 se-
quences is in agreement with the fact that the HTLV-1
genome exhibits relatively few sequence variations, em-
phasizing that recombinant envelope glycoproteins or
synthetic peptides could be used as an effective vaccine
candidate. This genomic stability and the presence of
neutralizing antibodies in HTLV-1-infected individuals
Table 2 Possible epitopes for classes I and II HLA alleles in HTLV-1 gp46 53-75 aa domain
A-Class I HLA alleles
AA position Epitope sequence HLA allele
52 L D L L A L S A D B 37
53 D L L A L S A D Q A 03
54 L L A L S A D Q A A 0201, A 03
55 L A L S A D Q A L A 0201, B 08, B 1402, B 5101
56 A L S A D Q A L Q A 03
57 L S A D Q A L Q P A 1101
62 A L Q P P C P N L A 0702, B 08, B 2705, B4402
63 L Q P P C P N L V B 3902
64 Q P P C P N L V G B 0702, B 5101
65 P P C P N L V G Y A 01, A 26, B 4402
68 P N L V G Y S S Y A 01
B-Class II HLA alleles
AA position Epitope sequence HLA allele
51 T L D L L A L S A D Q A L Q P DRB1 0101, DRB 0401
52 L D L L A L S A D Q A L Q P P DRB 0301, DRB 0701
54 L L A L S A D Q A L Q P P C P DRB1 0101, DRB 07071, DRB 1501
64 Q P P C P N L V G Y S S Y H A DRB1 0101
67 C P N L V G Y S S Y H A T Y S DRB1 0101, DRB 0401, DRB 0701, DRB 1501
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1 vaccine, and this could be an advantage comparing to
the challenge of developing a vaccine to HIV infection.
However, it is important to note that the sequences from
HAM/TSP individuals are relatively more divergent
compared to those from HC individuals, confirming that
the immune environment represents effective selective
pressure.
It is also worth noting that the relative lack of vari-
ation in the HTLV gp46 relative to the HIV gp120 is be-
lieved to reflect the fact that HTLV-1 persists in an
individual by clonal expansion of HTLV-1-infected cells,
rather than continual spread of the virus, as in HIV in-














The numbers superscript at the last column represents the results from the Exact F
different groups. *p = 0.028, §p = 0.0551, ¶p = 0.0022, Φp = 0.0283, †p = 0.0108, ‡p = 0.between geographical regions and certain HTLV-1 sub-
groups that can be associated with different risks of
HAM/TSP. Furthermore, a quarter of the provirus load
may be carried by CD8+ T cells and when equilibrium is
reached between a persistently replicating pathogen and
the immune response, the frequency of specific CD8+ T
cells is an unreliable index of the efficiency or effective-
ness of the T cell response [21].
We identified five common mutations in all 176 gp46
sequences. Four of the most common mutations (except
the V247I mutation) were associated to an intra-host pro-
file because were specifically found in the same single indi-
vidual: the S35L mutation was exclusive for one HC
individual, the F14S and G72S mutations were exclusiveh carriers and HAM/TSP individuals
HAM/TSP
(N = 76)









isher Test to the frequency of the potential protein domains in the two
0551, ≠p = 0.1047, Δp = 0.0108. N means the number of clones.
Figure 4 Physico-chemical analysis of wild type and mutated alleles of F14S, N42H and V247I polymorphisms. In Figure 4A (F14S), the
graphs are organized as follows: hydrophilicity for wild type allele, hydrophilicity for mutated allele, flexibility for wild type allele, and flexibility for
the mutated allele. In Figure 4B (N42H) and 4C (V247I), the graphs are organized as follows: antigenicity for wild type allele and antigenicity for
mutated allele.
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was exclusive for other HAM/TSP individual. Because of
this, we cannot associate any of these mutations to the
clinical profile, due to the reduced number of individuals
recruited in this study. Due to the observed intra-host pro-
file of the found mutations, we compared them to the pro-
viral load of each individual. The mutations S35L, F14L,
G72S and N42H were identified in individuals with high
proviral load (log > 5).
We suggest that future studies evaluating the molecular
diversity of envelope proteins should take into account a
larger number of individuals, and a reduced number of
clones. A larger number of individuals could be useful to
evaluate the association of the possible mutations to the
clinical status, while cloning could be useful for the identi-
fication of intra-host variations and possible emerging
changes. In this regard, three (F14S, S35L and N42H) of
these newly identified mutations can be classified as a
completely new protein characteristics, while the V247IFigure 5 HTLV-1 gp46 secondary structure prediction. The S35L (A) an
extended beta structure.mutation is an already known characteristic of Brazilian
HTLV-1 isolates.
We could identify that HTLV-1 gp46 from HC and
HAM/TSP individuals had different genetic diversity
profiles, especially in domains with prevalence of linear
epitopes. In these domains, we identified different epi-
topes between HC and HAM/TSP individuals. Recent
data revealed that patients with HAM/TSP recognized a
significantly broader repertoire of Env epitopes, com-
pared with health carriers, suggesting that the diversity,
frequency and repertoire of HTLV-1 Env CD8+ T-cells
may be related to the hyperimmune response in HAM/
TSP disease [22]. Additionally, the identification of the
Env epitopes associated with the immune system activa-
tion could be useful to vaccine design [23]. In a recent
report, the immunogenicity and protective efficacy in
squirrel monkeys of a B-cell env gene epitope and of a
T-cell multiepitope derived from Tri-Tax were tested.
The authors showed that the reduction in the number ofd G72S (B) polymorphisms were associated to the switch of coil to
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epitope peptide was much lower than with the B-cell
env gene epitope peptide, indicating the involvement of
other virus-specific T-cell subsets in this cellular im-
mune response [24]. These T-cell subsets could be those
ones that are specific to divergent viruses.
We believe in the potential of these mutations to be-
come clinical markers as they are located in important
protein domains. The fact that some of these mutations
have been associated to physico-chemical or secondary
structure changes does not mean that there is no need for
in vitro assays. This investigation is important because
antibodies are most likely to recognize linear epitopes but
they are also dependent on the conformation of the anti-
gen and efficient epitope recognition determines the neu-
tralizing properties of anti-HTLV-1 antibodies [25]. In this
case, non effective antibodies could be closely related to
the clinical manifestation because they can play an im-
portant role in controlling HTLV-1 dissemination and the
viral burden on natural infections, in particular through
antibody-dependent cellular cytotoxicity [26].
The genomic regions where the post-translational sites
were identified, showed a high identity among the se-
quences, suggesting the influence of these sites on the
host immune response, and virus latency. The post-
translational modifications in envelope glycoproteins are
not well documented therefore there is a lack of evi-
dence of the importance of these sites for virus clonal
expansion. However, these sites are frequently found in
HTLV-1 envelope proteins, and it would be interesting
to investigate the functional impact of them. Regarding
the Tax protein, for example, much is known about the
post-translational modifications and they are important
in the constitutive activation of NF-κB pathways, inhib-
ition of DNA repair, activation of p53 tumor suppressor
and cell cycle control [27].
The immune responses that differentiate health carrier
from HAM/TSP could be a result of the fact that infected
cells, which display the envelope on the surface, remain
insensitive and not vulnerable to antibody-dependent cel-
lular cytotoxicity and antibody-mediated complement fix-
ation. From the present results, our group is carrying out
a site-directed mutagenesis assay to test the impact of the
described mutations in the binding capacity of the variant
protein against natural antibodies produced by HC and
HAM/TSP individuals. The benefits of investigating these
mutations can also be useful for the Western Blot indeter-
minate profile which is dependent on the efficient binding
of gp46 and natural antibodies.
Conclusions
In conclusion, the results presented in this study suggest
that the most frequent gp46 mutations (F14S, N42H,
V247I and S35L), as well as, the mutations (H290D,C289R, F141S, D197N and F159S) associated to the loss
of a post-translational site should be evaluated in greater
detail, in particular the reactivity of the mutated proteins
against natural antibodies. Furthermore, we believe that
analyses involving a greater number of sequences can pro-
vide more information about the occurrence of these vari-
ations and the identification of others, which are just as
important as the ones presented here.
Methods
Patients
Blood samples were collected from 10 individuals who
were frequently seen at the Bahia School of Medicine
and Public Health, HTLV reference center in Salvador,
located in Northeastern Brazil, in the first period of
2010. This is a free public outpatient clinic that has pro-
vided comprehensive care to a total of 1,050 patients
since 2002. All 10 patients were included in the present
study with inclusion criteria consisting of an available
HTLV-1 proviral load measurement and a neurological
evaluation. All patients had a quite similar proviral load
and median of age. All cases of co-infection were ex-
cluded, as well as symptomatic patients with other HTLV-
1-associated diseases, such as infective dermatitis, uveitis,
ATLL, Sicca syndrome, etc. The Disability Status Scale
(DSS) [28] and the Osame Motor Disability Score (OMDS)
were regularly applied by a neurologist. This study was ap-
proved by the Ethical Committee (Protocol Number 81/
2007) of the Bahia School of Medicine and Public Health.
Informed consent was obtained from all enrolled patients.
Salvador is the capital of Bahia State in northeast Brazil
and presents wide socioeconomic differences. The popula-
tion is roughly 80% black or racially mixed African and
Portuguese descendents.
Measurement of HTLV-1 proviral load
PBMCs were obtained from EDTA blood by density gradi-
ent centrifugation. DNA was extracted using spin column
DNA extraction system (Qiagen, Hilden, Germany) and
HTLV-1 proviral load was quantified using a real-time
TaqMan Polymerase Chain Reaction (PCR) method, as de-
scribed previously [29]. Albumin DNA was used as an en-
dogenous reference. The value of HTLV-1 proviral load
was reported as the [(HTLV-1 average copy number)/
(albumin average copy number)] × 2 × 106 and expressed
as the number of HTLV-1 copies per 106 cells in PBMCs.
gp46 PCR and cloning
The gp46 coding sequences from the viruses isolated
from the PBMCs of HTLV-1-infected patients were
amplified by PCR. In brief, gp46F/gp46R (gp46F 50CGC
CGATCCCAAAGAAAAA30/gp46R 50ACATGGAGCCG
GTAATCCC30) were designed and used to amplify a
936pb fragment, corresponding to the entire gp46 coding
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Gel Extraction kit (Qiagen, QIAamp DNA miniKit, Qiagen,
Hilden, Düsseldorf, Germany). The amplicons were then li-
gated into the pCRW4-TOPO available at TOPO TA
cloningW kit for sequencing (Invitrogen, CA, USA), and the
mini preparations were made using the kit (WizardW Plus
Minipreps DNA Purification System). All purified clones
were sequenced in an ABI Prism 3100 DNA Sequencer
(Applied Biosystems Inc., Foster City, CA) using Taq FS
Dye (Applied Biosystems) terminator cycle sequencing.
Besides the same PCR primers, a new inner primer (gp46
R2 50GACGTGCCAAGTGGATAGGC30) was used to
optimize the sequencing reactions.
gp46 Molecular characterization
Before analyzing the obtained gp46 sequences for the
presence of mutations and identification of molecular cha-
racteristics, two datasets were constructed. The first was
called “Cosmopolita database” and was composed by 27
gp46 sequences from different countries (except from
Brazil), previously available in the NCBI/Nucleotide Se-
quence Database (GenBank). It is important to note
that the 27 sequences of the “Cosmopolita dataset” did
not have any information about subtype and were gene-
rated from different countries: French Guyana, Central
America (n = 7); Martinique, Central America (n = 1);
Gabon, Central Africa (n = 12); and Guadalupe, Central
America (n = 7). The second dataset was called “Brazilian
dataset” and was composed by 42 gp46 sequences from
Brazil, previously available in GenBank. It is therefore im-
portant to note that these 42 Brazilian sequences are clas-
sified as subtype a (Cosmopolita), and were generated
from different Brazilian geographic regions: Salvador,
Northern (n = 21); Londrina, South (n = 5); São Paulo,
Southeast (n = 11), while five of them did not present any
information about their geographic origin.
Both datasets were submitted separately to the Clustal X
software [30] to perform the alignment which was then
manually edited using the GeneDoc program [31], and fi-
nally, the edited alignments were used to generate a
unique consensus sequence of each dataset using Bioedit
software [32]. The consensus sequence from “Cosmopolita
database” was called “Cosmopolita reference” and the con-
sensus sequence from the “Brazilian dataset” was called
“Brazilian reference”. These consensus sequences comprise
the most frequent nucleotide variants found in previously
published gp46 sequences from Brazil and elsewhere. These
consensus sequences were used as the reference sequences
to identify possible mutations in the 146 newly generated
gp46 sequences.
The genetic distances were measured within the two
distinct groups: gp46 sequences from HC and HAM/TSP
HTLV-1 infected individuals. The Tamura Nei model was
used with a distance matrix implemented in the MEGA3.0 package [33], and the standard error computation was
obtained by Bootstrap analysis (1000 replicates). The mu-
tation/polymorphism identification was performedmanually
using the visualization of alignment in the Bioedit software.
To test the hypothesis that the amino acid substitutions
within the gp46 sequences could have been favored or not
by natural selection, the positive selection was assessed
using six different codon-based maximum-likelihood sub-
stitution models [34]. All models were implemented in the
HYPHY program [35] and the ω and p values were esti-
mated through maximum-likelihood optimization, in such
a way that using the M3 model, sites with a posterior
probability exceeding 90% and a ω value > 1 were labeled
as being “positive selection sites”. Finally, Likelihood Ratio
Test (LRT) analysis was used to determine: (1) if site he-
terogeneity selection was present and (2) if there were
positively selected sites [23,36].
Epitope prediction was carried out for the HC and
HAM/TSP consensus sequences to 27 HLA-I (HLA
A1101, HLA A26, HLA B1510, HLA B4402, HLA A01,
HLA A0201, HLA A2402, HLA A5101, HLA A03, HLA
B2705, HLA A6801, HLA B08, HLA B0702, HLA
B2709, HLA B 1402, HLA B1501, HLA B18, HLA B37,
HLA B3801, HLAB 3901, HLA B 3902, HLA B4001,
HLA B4101, HLA B 4501, HLA B 4701, HLA B 4901,
HLA B5101) and 6 HLA-II alleles (HLA DRB1 0101,
HLA DRB1 0401, HLA DRB1 0301, HLA DRB1 1501,
HLA DRB1 0701, HLA DRB1 1101), using the online
bioinformatics tool SYFPEITHI (http://www.syfpeithi.de/
Scripts/MHCServer.dll/Epitope Prediction.htm) [37]. This
tool uses an algorithm that can predict sequences that
have the potential ability to bind to one or more different
HLA-I and HLA-II molecules. It also provides infor-
mation about the epitope sequence, the specificity to the
HLA molecule and the HLA binding score for each
epitope.
To investigate the possible influence of the described
mutations in the gp46 sequences, physico-chemical ana-
lysis was performed using Network Protein Sequence
Analysis (NPSA) (http://npsa-pbil.ibcp.fr/) [38-42] and the
potential protein domain analysis using the GeneDoc soft-
ware and the Prosite tool, as previously described [43].
Finally, the SWISS-MODEL online tool (http://swiss
model.expasy.org/) [44] was used as a fully automated
protein structure homology-modeling server, to infer the
possible influence of the amino acid changes at protein
secondary structure.
All env nucleotide sequences previously deposited in the
GenBank and used in the study are listed below with
their corresponding accession number: [L26585, L26586,
L33265, L33266, AF091494-AF091500, AF092065, L76041-
L76049, L76052-L76054, L76056, L76058, L76060,
DQ007189-DQ007209, HM770426-HM770440, U81865-
U81869, AF077209].
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